We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's Gardasil Gets FDA Approval for Head and Neck Cancers
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) announced that the FDA has granted accelerated approval to a supplemental biologics license application seeking label expansion of Gardasil 9 vaccine for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus (“HPV”) types 16, 18, 31, 33, 45, 52, and 58 in females and males 9 through 45 years of age.
Continued approval of the vaccine in these indications may be contingent upon verification and description of clinical benefit in a confirmatory study. The company is currently conducting a similar study to support the vaccine’s continued approval.
Gardasil 9 is already approved as a prevention for cervical, vaginal, vulvar and anal cancers caused by certain HPV types in patients aged 9 through 45 years.
Merck’s shares have declined 16.1% this year so far compared with the industry’s increase of 5.1%.
Vaccine is an important therapeutic area for Merck. The human papillomavirus vaccine, Gardasil/Gardasil 9 is a key top-line driver forthe company, recording sales of more than $1.1 billion in the first quarter of 2020 and representing year-over-year growth of more than 30%. The current label expansion of the vaccine will further boost its sales going forward. Apart from Gardasil, the company has several marketed vaccines in its portfolio like ProQuad/M-M-R II/Varivax, RotaTeq, Pneumovax 23 and Zostavax.
The company received approval for an Ebola vaccine, Ervebo, in December last year. Merck is studying an investigational 15-valent pneumococcal conjugate vaccine candidate, V114, in late-stage studies. The candidate is being developed as a preventive treatment for invasive pneumococcal disease in pediatric as well as adult patients.
Merck currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the large-cap pharma sector include Eli Lilly and Company (LLY - Free Report) , AbbVie Inc. (ABBV - Free Report) and AstraZeneca (AZN - Free Report) . While Eli Lilly currently sports a Zacks Rank #1 (Strong Buy), AbbVie and AstraZeneca presently hold a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Lilly’s earnings estimates have moved up from $6.77 to $6.81 for 2020 and from $7.92 to $8.02 for 2021 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average beat of 8.24%. Its shares have risen9.2% so far this year.
AbbVie’s earnings estimates have moved up from $9.81 to $10.54 for 2020 and from $11.28 to $12.03 for 2021 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with the average being 2.77%. Shares have gained4.4% so far this year.
AstraZeneca’s earnings estimates have moved up from $2.01 to $2.03 for 2020 and from $2.57 to $2.61 for 2021 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with the average beat being6.11%. Shares have risen3.2% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Shutterstock
Merck's Gardasil Gets FDA Approval for Head and Neck Cancers
Merck & Co., Inc. (MRK - Free Report) announced that the FDA has granted accelerated approval to a supplemental biologics license application seeking label expansion of Gardasil 9 vaccine for the prevention of oropharyngeal and other head and neck cancers caused by human papillomavirus (“HPV”) types 16, 18, 31, 33, 45, 52, and 58 in females and males 9 through 45 years of age.
Continued approval of the vaccine in these indications may be contingent upon verification and description of clinical benefit in a confirmatory study. The company is currently conducting a similar study to support the vaccine’s continued approval.
Gardasil 9 is already approved as a prevention for cervical, vaginal, vulvar and anal cancers caused by certain HPV types in patients aged 9 through 45 years.
Merck’s shares have declined 16.1% this year so far compared with the industry’s increase of 5.1%.
Vaccine is an important therapeutic area for Merck. The human papillomavirus vaccine, Gardasil/Gardasil 9 is a key top-line driver forthe company, recording sales of more than $1.1 billion in the first quarter of 2020 and representing year-over-year growth of more than 30%. The current label expansion of the vaccine will further boost its sales going forward. Apart from Gardasil, the company has several marketed vaccines in its portfolio like ProQuad/M-M-R II/Varivax, RotaTeq, Pneumovax 23 and Zostavax.
The company received approval for an Ebola vaccine, Ervebo, in December last year. Merck is studying an investigational 15-valent pneumococcal conjugate vaccine candidate, V114, in late-stage studies. The candidate is being developed as a preventive treatment for invasive pneumococcal disease in pediatric as well as adult patients.
Merck Co., Inc. Price
Merck Co., Inc. price | Merck Co., Inc. Quote
Zacks Rank and Stocks to Consider
Merck currently has a Zacks Rank #3 (Hold). Some better-ranked stocks in the large-cap pharma sector include Eli Lilly and Company (LLY - Free Report) , AbbVie Inc. (ABBV - Free Report) and AstraZeneca (AZN - Free Report) . While Eli Lilly currently sports a Zacks Rank #1 (Strong Buy), AbbVie and AstraZeneca presently hold a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Lilly’s earnings estimates have moved up from $6.77 to $6.81 for 2020 and from $7.92 to $8.02 for 2021 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with average beat of 8.24%. Its shares have risen9.2% so far this year.
AbbVie’s earnings estimates have moved up from $9.81 to $10.54 for 2020 and from $11.28 to $12.03 for 2021 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters, with the average being 2.77%. Shares have gained4.4% so far this year.
AstraZeneca’s earnings estimates have moved up from $2.01 to $2.03 for 2020 and from $2.57 to $2.61 for 2021 over the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with the average beat being6.11%. Shares have risen3.2% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>